We are live on ! Find out more
UNCY icon

Unicycive Therapeutics
UNCY

34 hedge funds and large institutions have $47M invested in Unicycive Therapeutics in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

72% more capital invested

Capital invested by funds: $27.4M → $47M (+$19.6M)

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

13% more funds holding

Funds holding: 30 → 34 (+4)

2.31% more ownership

Funds ownership: 35.59% → 37.9% (+2.3%)

Holders
34
Holders Change
+4
Holders Change %
+13.33%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
8
Reduced
6
Closed
2
Calls
$342K
Puts
–
Net Calls
+$342K
Net Calls Change
+$342K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$5.42M
2
Citadel Advisors
Citadel Advisors
Florida
+$1.16M
3
CF
Cantor Fitzgerald
New York
+$1.07M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$692K
5
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$532K

Top Sellers

Rank Fund Capital Flow
1
Squarepoint
Squarepoint
New York
-$331K
2
Goldman Sachs
Goldman Sachs
New York
-$197K
3
Citigroup
Citigroup
New York
-$34.5K
4
CPIG
Chicago Partners Investment Group
Illinois
-$24.3K
5
XT
XTX Topco
Cayman Islands
-$12.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
1
Vivo Capital
California
$10.3M – – –
Millennium Management
2
Millennium Management
New York
$5.86M +$5.42M +1,014,843 New
OCA
3
Octagon Capital Advisors
New York
$5.77M – – –
NCM
4
Nantahala Capital Management
Connecticut
$5.42M – – –
GPP
5
Great Point Partners
Connecticut
$4.6M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$4.55M +$692K +129,709 +20%
LGM
7
Logos Global Management
California
$2.73M – – –
Citadel Advisors
8
Citadel Advisors
Florida
$1.49M +$1.16M +216,627 +520%
CF
9
Cantor Fitzgerald
New York
$1.15M +$1.07M +200,000 New
Geode Capital Management
10
Geode Capital Management
Massachusetts
$989K +$243K +45,563 +36%
BNP Paribas Financial Markets
11
BNP Paribas Financial Markets
France
$576K +$532K +99,687 +181,249%
DIG
12
Dauntless Investment Group
New Hampshire
$516K +$477K +89,415 New
OAC
13
OMERS Administration Corp
Ontario, Canada
$451K +$417K +78,200 New
State Street
14
State Street
Massachusetts
$376K +$55.5K +10,400 +19%
ACP
15
Acuta Capital Partners
California
$346K – – –
Squarepoint
16
Squarepoint
New York
$319K -$331K -62,022 -53%
Morgan Stanley
17
Morgan Stanley
New York
$269K +$192K +35,972 +339%
QC
18
Quadrature Capital
United Kingdom
$226K +$209K +39,114 New
BlackRock
19
BlackRock
New York
$210K – – –
Northern Trust
20
Northern Trust
Illinois
$207K +$17.3K +3,238 +10%
XT
21
XTX Topco
Cayman Islands
$204K -$12.9K -2,418 -6%
CPIG
22
Chicago Partners Investment Group
Illinois
$155K -$24.3K -4,548 -17%
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$144K +$133K +24,931 New
UBS Group
24
UBS Group
Switzerland
$115K +$77.2K +14,460 +266%
TRCT
25
Tower Research Capital (TRC)
New York
$11.1K +$10.3K +1,920 New
1
2

UNCY Hedge Fund Activity: Q4 2025 in Review

34 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q4 2025, worth a combined $47M — up 72% from $27.4M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new UNCY positions and 2 closed out — a net gain of 5 holders — while 8 added to existing stakes and 6 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $5.42M. The largest seller was Squarepoint, cutting an estimated $331K.

  • 34 institutional investors held Unicycive Therapeutics (UNCY) as of Q4 2025, up from 30 in Q3 2025.
  • Funds reported $47M of Unicycive Therapeutics stock for Q4 2025, up 72% quarter-over-quarter.
  • 7 funds opened new Unicycive Therapeutics positions in Q4 2025 and 2 closed out, a net change of +5 holders.
  • The largest Unicycive Therapeutics buyer in Q4 2025 was Millennium Management, an estimated $5.42M added.
  • The largest Unicycive Therapeutics seller in Q4 2025 was Squarepoint, an estimated $331K sold.

Based on aggregated 13F filings for Q4 2025.